Team:UCSF/SandBox
From 2010.igem.org
(51 intermediate revisions not shown) | |||
Line 2: | Line 2: | ||
<style> | <style> | ||
body{ | body{ | ||
- | background-color:#494d51; | + | //background-color:white;//#494d51; |
} | } | ||
h1{ | h1{ | ||
Line 14: | Line 14: | ||
text-indent: 10px; | text-indent: 10px; | ||
} | } | ||
- | p, pre{ | + | #left p, #left pre{ |
margin-left:35px; | margin-left:35px; | ||
margin-right:35px; | margin-right:35px; | ||
Line 21: | Line 21: | ||
text-align:justify; | text-align:justify; | ||
} | } | ||
- | h3{ | + | #left h3{ |
font-weight:normal; | font-weight:normal; | ||
text-vertical-align:middle; | text-vertical-align:middle; | ||
Line 38: | Line 38: | ||
} | } | ||
div#top-section{ | div#top-section{ | ||
- | background-color:# | + | background-color:#FF535D; |
- | width: | + | width:959px; |
height: 24px; | height: 24px; | ||
border:none; | border:none; | ||
Line 57: | Line 57: | ||
//display: none; | //display: none; | ||
//text-indent:10px; | //text-indent:10px; | ||
- | top: | + | top: 0px; |
+ | color:black; | ||
} | } | ||
+ | |||
div#p-logo{ | div#p-logo{ | ||
display: none; | display: none; | ||
Line 68: | Line 70: | ||
} | } | ||
#content{ | #content{ | ||
+ | background-image:url(https://static.igem.org/mediawiki/2010/4/45/UCSF_DropShadow.png); | ||
+ | background-repeat:vertical; | ||
margin-top:-24px; | margin-top:-24px; | ||
- | padding-left: | + | padding-left:8px; |
- | padding-right: | + | border:none; |
+ | padding-right:8px; | ||
padding-top:2px; | padding-top:2px; | ||
z-index:0; | z-index:0; | ||
- | width: | + | width:959px; |
} | } | ||
+ | #footer-box{ | ||
+ | background-image:url(https://static.igem.org/mediawiki/2010/d/df/UCSF_FooterDropShadow.png); | ||
+ | background-position:center bottom; | ||
+ | background-repeat:no-repeat; | ||
+ | width:955px; | ||
+ | padding-left:10px; | ||
+ | padding-right:10px; | ||
+ | padding-bottom:10px; | ||
+ | border:none; | ||
+ | margin-bottom:24px; | ||
+ | } | ||
+ | |||
#navigation ul, | #navigation ul, | ||
#navigation li{ | #navigation li{ | ||
Line 225: | Line 242: | ||
#banner{ | #banner{ | ||
margin-top:24px; | margin-top:24px; | ||
- | width: | + | width:957px; |
overflow:hidden; | overflow:hidden; | ||
margin-left:auto; | margin-left:auto; | ||
Line 231: | Line 248: | ||
} | } | ||
#Main{ | #Main{ | ||
- | width: | + | width:959px; |
overflow:hidden; | overflow:hidden; | ||
margin-top:2px; | margin-top:2px; | ||
Line 244: | Line 261: | ||
</html> | </html> | ||
{{Template:UCSF/Nav}} | {{Template:UCSF/Nav}} | ||
+ | |||
<html> | <html> | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
<style type="text/css"> | <style type="text/css"> | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
.searchform { | .searchform { | ||
+ | margin-left:3px; | ||
+ | // margin-right:auto; | ||
+ | margin-top:3px; | ||
display: inline-block; | display: inline-block; | ||
zoom: 1; /* ie7 hack for display:inline-block */ | zoom: 1; /* ie7 hack for display:inline-block */ | ||
*display: inline; | *display: inline; | ||
- | border: solid 1px #d2d2d2; | + | //border: solid 1px #d2d2d2; |
padding: 3px 5px; | padding: 3px 5px; | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
} | } | ||
.searchform input { | .searchform input { | ||
Line 296: | Line 281: | ||
background: #fff; | background: #fff; | ||
padding: 6px 6px 6px 8px; | padding: 6px 6px 6px 8px; | ||
- | width: | + | width: 184px; |
border: solid 1px #bcbbbb; | border: solid 1px #bcbbbb; | ||
outline: none; | outline: none; | ||
Line 328: | Line 313: | ||
</style> | </style> | ||
+ | <table border="0" style="margin:0px;padding:0px;margin-top:-25px;"> | ||
+ | <tbody> | ||
+ | <tr> | ||
+ | <td width="707px" style="padding: 0 0 0 0; background-color:#ede8e2;margin:0;" valign="top"> | ||
- | <div id="left"> | + | <div id="left" style="width:100%;height:100%;"> |
+ | </html> | ||
+ | ===Project Description=== | ||
- | <form method="get" action="http://www.google.com/search"> | + | Natural killer (NK) cells of the immune system identify cancer and virally-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, NK cells use a variety of receptors, which bind to specific ligands at the target cells’ surface. The balance between activating and inhibitory signals will tell the NK cell if the target cell is diseased or healthy, respectively. If the target cell is deemed potentially dangerous, the NK cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the NK cell releases cytotoxic granules to kill the target cell without harming any nearby cells allowing for a direct, apoptotic death. |
+ | |||
+ | Our team will focus on improving NK cells’ specificity and killing efficiency towards certain cancer types. By using synthetic biology tools and logic gates’ design, we hope to create powerful killing biomachines for the fight against cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients. | ||
+ | <html> | ||
+ | </div> | ||
+ | </td> | ||
+ | </html> | ||
+ | <html> | ||
+ | <td width="250px" style="padding: 0 0 0 0; background-color:#d8d5d0;margin:0;" valign="top"> | ||
+ | <div id="right" style="width:100%;height:100%;"> | ||
+ | <form class="searchform" method="get" action="http://www.google.com/search"> | ||
<input type="text" class="searchfield" name="q" size="25" | <input type="text" class="searchfield" name="q" size="25" | ||
maxlength="255" value="" /> | maxlength="255" value="" /> | ||
<input type="submit" class="searchbutton" value="Go" /> | <input type="submit" class="searchbutton" value="Go" /> | ||
- | <input type="checkbox" name="sitesearch" value="2010.igem.org/Team:UCSF" checked /> | + | <input type="checkbox" style="display:none;" name="sitesearch" value="2010.igem.org/Team:UCSF" checked /> |
- | + | ||
</form> | </form> | ||
- | |||
</html> | </html> | ||
- | |||
- | |||
- | + | '''RIGHT CONTENT'''<br> | |
- | + | replace this area with your content. | |
- | + | ||
<html> | <html> | ||
- | < | + | </div> |
- | + | </td> | |
- | + | </tr> | |
- | + | </tbody> | |
- | + | </table> | |
- | + | <div style="border-bottom:1px black dashed;height:10px;"></div> | |
+ | </div> | ||
+ | <script> | ||
+ | var list = Numbering.split(" "); | ||
+ | for(var i=0;i<list.length;i++){ | ||
+ | var Item = document.getElementById(list[i]); | ||
+ | var cn = Item.className; | ||
+ | Item.className=cn+" active"; | ||
} | } | ||
- | </ | + | </script> |
- | + | ||
</html> | </html> | ||
- | |||
- | |||
- | |||
- | |||
- | |||
__NOTOC__ | __NOTOC__ |
Latest revision as of 14:25, 26 October 2010
Project DescriptionNatural killer (NK) cells of the immune system identify cancer and virally-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, NK cells use a variety of receptors, which bind to specific ligands at the target cells’ surface. The balance between activating and inhibitory signals will tell the NK cell if the target cell is diseased or healthy, respectively. If the target cell is deemed potentially dangerous, the NK cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the NK cell releases cytotoxic granules to kill the target cell without harming any nearby cells allowing for a direct, apoptotic death. Our team will focus on improving NK cells’ specificity and killing efficiency towards certain cancer types. By using synthetic biology tools and logic gates’ design, we hope to create powerful killing biomachines for the fight against cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients. |
|